|BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019|
March 18, 2019
|ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 18, 2019--
Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that Brian M.
Culley, Chief Executive Officer, will be presenting at the Oppenheimer &
Co. 29th Annual Healthcare Conference on March 20th,
2019 at 2:45pm Eastern Time at the Westin New York Grand Central in the
Track 2 Room in New York, NY.
|BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update|
March 14, 2019
|Completed Acquisition of Asterias Biotherapeutics, Inc.
Completed Distribution of AgeX Therapeutics Shares to BioTime
Entered Into Exclusive Collaboration with Orbit Biomedical Ltd.
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 14, 2019--
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company focused on degenerative diseases, reported
financial and operating resul... |
|BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company|
March 11, 2019
|Company Will Advance Three Clinical Stage Product Candidates
Addressing Significant Unmet Needs in Dry-AMD, Spinal Cord Injury, and
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 11, 2019--
Inc. (NYSE American and TASE: BTX), today announced the closing of
its previously reported acquisition of Asterias Biotherapeutics, Inc.
(Asterias), whereby BioTime has acquired through a merger, all of the
remaining outstanding comm... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|